**Supplementary Table 3**. **Individual metabolite response to antibiotic treatment common between *in vitro* grown MRSA and MSSA and mice infected with MRSA and MSSA.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Metabolitea | Change in concentration with effective treatmentb | Three independent *in vitro* experiments | | | | Mice infection | | |
|  |  | **RIc** | **p-valued** | | **w\*e** | **RIc** | **p-valued** | **w\*e** |
| Carbohydrate | ↑ | 2020/2019/2015 | | \*\*\*/ \*\*\*/ \*\*\* | \*/\*/\* | 2018 | \*\*\* | \* |
| Glucose | ↑ | 1910/1910/1905 | | \*/ \*/ \*\*\* | \*/\*/\* | 1915 | \*\*\* | \* |
| Glycine | ↑ | 1308/1307/1306 | | \*\*\*/ \*\*\*/ \*\*\* | \*/\*/\* | 1302 | \* | \* |
| Malic acid | ↓ | 1486/1485/1484 | | / / \* | \*/\*/\* | 1483 | \*\*\* | \* |
| Ribitol | ↓ | 1719/1717/1714 | | / / \*\* | \*/\*/\* | 1711 |  | \* |
| Serine | ↑ | 1362/1360/1359 | | \*\*\*/ \*\*\*/ \*\*\* | \*/\*/\* | 1358 | \*\* | \* |
| Tyrosine | ↑ | 1941/1940/1938 | | \*\*/ \*\*/ \*\* | \*/\*/\* | 1937 | \* | \* |
| Unid L | ↑ | 1761/1760/1758 | | \*/ / \*\* | \*/\*/\* | 1760 |  | \* |
| Unid P | ↑ | 2630/2630/2624 | | \*/ \*/ \*\*\* | \*/\*/\* | 2629 |  | \* |

aSignificant metabolites common between three in vitro experiments and one mouse experiment with MRSA and MSSA.

bRefers to response to antibiotic treatment, where ↑/↓ indicates a higher/lower metabolite concentration in samples with effective treatment compared to samples with ineffective treatment

cRetention index for all metabolites.

dSignificance regarding p-values is stated with \* for p < 0.05, \*\* for p < 0.01 and \*\*\* for p < 0.001.

eSignificance regarding w\* is stated with \* for -0.04 > w\* > 0.04.